AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27495137 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing
Number of subjects: 2037
Study 27495137 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2037
Study 25196314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study 23015563 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique
Number of subjects: 60
Study 23015563 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique
Number of subjects: 60
Study 23015563 — intervention group
Group type: EXPERIMENTAL
Intervention: AM bundle in double-bundle group
Number of subjects: 60
Study 23015563 — intervention group
Group type: EXPERIMENTAL
Intervention: PL bundle in double-bundle technique
Number of subjects: 60
Study 21034545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity induction with 8% sevoflurane at 6 L/min
Number of subjects: 51
Study 21034545 — intervention group
Group type: COMPARATOR
Intervention: Tidal breathing induction with 8% sevoflurane at 6 L/min
Number of subjects: 51
Study 21034545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity induction
Number of subjects: 51
Study 21034545 — intervention group
Group type: COMPARATOR
Intervention: Tidal breathing induction
Number of subjects: 51
Study 17413870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 0
Study 17413870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 0
Study 17413870 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 16351335 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Head Start program
Number of subjects: 3001
Study 16351335 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Head Start program with a mix of home-visiting and center-based services
Number of subjects: 3001
Study 16351335 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3001
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative feedback
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Light force conditions
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy force conditions
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial blocks
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention phase
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Time between acquisition and retention trials
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial blocks during retention phase
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Group trial block interaction for /CE/
Number of subjects: 71
Study 11898016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 71
Study 10437419 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg
Number of subjects: 165
Study 10437419 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 165
Study 10437419 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 165
Study 7568344 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 7
Study 7568344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1968919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg (three daily doses)
Number of subjects: 16
Study 1968919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (5, 10, and 20 mg)
Number of subjects: 16
Study 1968919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine and Albuterol
Number of subjects: 16
Study 1968919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1968919 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 4 mg
Number of subjects: 16
Study 395955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (3 x 1 dragée at 10 mg for 12 weeks)
Number of subjects: 56
Study 395955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30932154 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health warning labels present on cigarette packages
Number of subjects: 294
Study 30932154 — intervention group
Group type: COMPARATOR
Intervention: Cigarette packages without graphic health warning labels
Number of subjects: 294
Study 28631849 — intervention group
Group type: EXPERIMENTAL
Intervention: automated closed-loop therapy
Number of subjects: 16
Study 28631849 — intervention group
Group type: COMPARATOR
Intervention: sensor-augmented pump therapy
Number of subjects: 16
Study 26392766 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg)
Number of subjects: 40
Study 26392766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23404882 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring/Task-Involving (C/TI) climate
Number of subjects: 107
Study 23404882 — intervention group
Group type: COMPARATOR
Intervention: Ego-Involving (EI) climate
Number of subjects: 107
Study 20965155 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous estrogen exposure
Number of subjects: 53
Study 20965155 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of reproductive years of life
Number of subjects: 53
Study 20965155 — intervention group
Group type: COMPARATOR
Intervention: Length of hormone therapy (HT) use
Number of subjects: 53
Study 19845991 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report data collection
Number of subjects: 175
Study 19845991 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provider registrations
Number of subjects: 175
Study 19845991 — intervention group
Group type: COMPARATOR
Intervention: Hospitalizations
Number of subjects: 175
Study 19845991 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist visits
Number of subjects: 175
Study 19845991 — intervention group
Group type: COMPARATOR
Intervention: All other types of care
Number of subjects: 175
Study 16150840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity exposure in supine posture
Number of subjects: 4
Study 16150840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity exposure in prone posture
Number of subjects: 4
Study 15701187 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted hysterectomy
Number of subjects: 46
Study 15701187 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 46
Study 11699735 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush (experimental toothbrush)
Number of subjects: 40
Study 11699735 — intervention group
Group type: COMPARATOR
Intervention: Colgate Navigator (control toothbrush)
Number of subjects: 40
Study 9183201 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 6
Study 9183201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8314427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education
Number of subjects: 817
Study 8314427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 817
Study 8314427 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to general population
Number of subjects: 817
Study 2882420 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary‐artery bypass surgery plus medical therapy
Number of subjects: 468
Study 2882420 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 468
Study 29164661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouthrinse
Number of subjects: 163
Study 29164661 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free mouthrinse
Number of subjects: 163
Study 26545320 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet or anticoagulant drugs
Number of subjects: 1185
Study 26545320 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet or anticoagulant drugs
Number of subjects: 1185
Study 24499060 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIMATE Schools Combined intervention
Number of subjects: 8400
Study 24499060 — intervention group
Group type: COMPARATOR
Intervention: CLIMATE Schools - Substance Use
Number of subjects: 8400
Study 24499060 — intervention group
Group type: COMPARATOR
Intervention: CLIMATE Schools - Mental Health
Number of subjects: 8400
Study 24499060 — intervention group
Group type: COMPARATOR
Intervention: Control (Health and Physical Education as usual)
Number of subjects: 8400
Study 22527794 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (REV)
Number of subjects: 1505
Study 22527794 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (MED)
Number of subjects: 1505
Study 22527794 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1505
Study 22527794 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1505
Study 22527794 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion abnormalities
Number of subjects: 1505
Study 20128041 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Recipe
Number of subjects: 60
Study 20128041 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Recipe combined with chemotherapy
Number of subjects: 60
Study 20128041 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (vinorelbine plus cisplatin or gemcitabine plus cisplatin)
Number of subjects: 60
Study 18154417 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapapillary needle‐knife fistulotomy (group B)
Number of subjects: 218
Study 18154417 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation (group A)
Number of subjects: 218
Study 16417182 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast added to previous medication for asthma treatment (4 weeks duration)
Number of subjects: 703
Study 16417182 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast added to previous medication for asthma treatment (8 weeks duration)
Number of subjects: 703
Study 12218520 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg)
Number of subjects: 70
Study 12218520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10604663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 205
Study 10604663 — intervention group
Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 205
Study 10604663 — intervention group
Group type: EXPERIMENTAL
Intervention: All eyes with mild to moderate nonproliferative diabetic retinopathy before lens surgery
Number of subjects: 205
Study 10604663 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with severe nonproliferative or worse retinopathy before lens surgery
Number of subjects: 205
Study 10604663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens surgery
Number of subjects: 205
Study 7550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromfenac
Number of subjects: 75
Study 7550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 75
Study 7550184 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill Pain Questionnaire (MPQ)
Number of subjects: 75
Study 7550184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm Visual Analogue Scale
Number of subjects: 75
Study 7550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Four word scale
Number of subjects: 75
Study 1709239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.1 nmol kg‐1 min‐1 (ADR‐L, n=8)
Number of subjects: 35
Study 1709239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.4 nmol kg‐1 min‐1 (ADR‐H, n=7)
Number of subjects: 35
Study 1709239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (color-word conflict test, CWT, n=10)
Number of subjects: 35
Study 1709239 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo, n=10)
Number of subjects: 35
Study 7029696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide plus amitriptyline
Number of subjects: 61
Study 7029696 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 61
Study 6543846 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated nose drops
Number of subjects: 74
Study 6543846 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline nose drops
Number of subjects: 74
Study 6543846 — intervention group
Group type: COMPARATOR
Intervention: No nose drops (Control)
Number of subjects: 74
Study 30464436 — intervention group
Group type: COMPARATOR
Intervention: 490 m
Number of subjects: 40
Study 30464436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,590 m
Number of subjects: 40
Study 30464436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,650 m
Number of subjects: 40
Study 30464436 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher altitudes (1,650 m and 2,590 m)
Number of subjects: 40
Study 30464436 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher altitudes
Number of subjects: 40
Study 26343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 0.11 to 0.44 mg and 0.33, 0.66 and 1 mg
Number of subjects: 6
Study 24927691 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LRYGB)
Number of subjects: 14
Study 24927691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (LSG)
Number of subjects: 14
Study 24927691 — intervention group
Group type: COMPARATOR
Intervention: Overall (both LRYGB and LSG)
Number of subjects: 14
Study 23194480 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term DAPT (3 months)
Number of subjects: 3120
Study 23194480 — intervention group
Group type: COMPARATOR
Intervention: Long-term DAPT (12 months)
Number of subjects: 3120
Study 20044312 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 223
Study 20044312 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 223
Study 18606439 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (neoadjuvant chemotherapy) followed by surgery
Number of subjects: 142
Study 18606439 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery
Number of subjects: 142
Study 16014046 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 20
Study 16014046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12114362 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (TOBI), 300 mg, delivered by nebulizer, twice daily, in three 28-day on/28-day off treatment cycles
Number of subjects: 258
Study 10403163 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 95
Study 10403163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 95
Study 10403163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Number of subjects: 0
Study 7668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride
Number of subjects: 0
Study 7668873 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 0
Study 7668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron combined with other antiemetic drugs
Number of subjects: 0
Study 2205418 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intravenous streptokinase
Number of subjects: 11712
Study 2205418 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intravenous streptokinase within 3 hours of onset of symptoms
Number of subjects: 11712
Study 2205418 — intervention group
Group type: COMPARATOR
Intervention: Secondary ventricular fibrillation
Number of subjects: 11712
Study 7449042 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise (HIE)
Number of subjects: 30
Study 7449042 — intervention group
Group type: COMPARATOR
Intervention: Light Intensity Exercise (LIE)
Number of subjects: 30
Study 31336474 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention via SMS
Number of subjects: 160
Study 31336474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 29129611 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep condition (SS): 4h/night (2:00-6:00)
Number of subjects: 16
Study 29129611 — intervention group
Group type: COMPARATOR
Intervention: Control sleep condition (CS): 7h/night (23:00-6:00)
Number of subjects: 16
Study 27445266 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplate‐ADP measurements
Number of subjects: 170
Study 27445266 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplate‐ADP (<50 AUC)
Number of subjects: 170
Study 27445266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels <2.5 g/L
Number of subjects: 170
Study 27445266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate analysis of body mass index, myocardial infarction, and multiplate‐ADP
Number of subjects: 170
Study 27445266 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable linear regression analysis of multiplate‐ADP
Number of subjects: 170
Study 24089423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 68
Study 24089423 — intervention group
Group type: COMPARATOR
Intervention: Recreational activity
Number of subjects: 68
Study 22147444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²/week for 4 weeks)
Number of subjects: 24
Study 22147444 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (maintenance or increase in immunosuppressive therapy)
Number of subjects: 24
Study 19561014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block with bupivacaine
Number of subjects: 52
Study 19561014 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 52
Study 17555006 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 69
Study 17555006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15811355 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 54
Study 15811355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied three times a week
Number of subjects: 0
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied once daily
Number of subjects: 0
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied twice daily
Number of subjects: 0
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied three times a day
Number of subjects: 0
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 11318254 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosing frequency (from three times a week to three times a day)
Number of subjects: 0
Study 9137677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (221 ± 60 mg daily)
Number of subjects: 71
Study 9137677 — intervention group
Group type: COMPARATOR
Intervention: Flecainide (165 ± 49 mg daily)
Number of subjects: 71
Study 9137677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 71
Study 9137677 — intervention group
Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 71
Study 9137677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline and Flecainide
Number of subjects: 71
Study 7955972 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell antibodies (ICA) testing in previous GDM patients
Number of subjects: 241
Study 7955972 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell antibodies (ICA) positivity
Number of subjects: 241
Study 7955972 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin autoantibodies (IAA) testing
Number of subjects: 241
Study 7955972 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA testing in GDM patients
Number of subjects: 241
Study 7955972 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-negative patients
Number of subjects: 241
Study 3555788 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT regimen (daunorubicin 70 mg/m2/day on Days 1‐3, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Number of subjects: 97
Study 3555788 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD regimen (daunorubicin 70 mg/m2/day on Days 5‐7, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Number of subjects: 97
Study 31340787 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Support Programme (BSP)
Number of subjects: 138
Study 31340787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BSP)
Number of subjects: 138
Study 28425747 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session psychiatric treatment augmented with the responsive intervention of the motive-oriented therapeutic relationship
Number of subjects: 57
Study 28425747 — intervention group
Group type: COMPARATOR
Intervention: 10-session psychiatric treatment
Number of subjects: 57
Study 25873092 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong EA (high-intensity current 2 mA < current < 5 mA)
Number of subjects: 450
Study 25873092 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak EA (low-intensity current 0 mA < current < 0.5 mA)
Number of subjects: 450
Study 25873092 — intervention group
Group type: COMPARATOR
Intervention: Sham EA (low-intensity current 0 mA < current < 0.5 mA, superficial needle insertion)
Number of subjects: 450
Study 23410714 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraception (NHC)
Number of subjects: 24
Study 23410714 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (ENG-I)
Number of subjects: 24